All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, sponsored by Autolus, Biogen and Biogen MA, Inc. and UCB. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View lupus content recommended for you
ACR 2026 | Top abstracts: What’s hot in lupus?
Featured:
Betty Diamond
Murray Urowitz
Ricard Cervera
Manuel Francisco Ugarte-Gil
Mandana Nikpour
James Cheng-Chung Wei
Jill Buyon
Laurent Arnaud
Ioannis Parodis
Gaurav Gulati
François Chasset
Victoria Werth
To help navigate the exciting content being presented at the American College of Rheumatology (ACR) Convergence 2026, November 6–11, 2026, Orlando, US, the Lupus Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in lupus.
| Oral presentations: Sunday, November 8 | |||
| Abstract | Title | Presenter | Time (EST) |
| 0872 | Litifilimab improves clinician and patient reported skin changes in cutaneous lupus erythematosus: 52-week results from the phase 2 study, AMETHYST Part A | Joseph Merola | 08:30–08:45 |
| 0875 | Nipocalimab in SLE: First-in-class efficacy and safety results demonstrating proof of concept for FcRn blockade from a phase 2 study | Richard Furie | 09:15–09:30 |
| 0921 | Assessment of renal, hematological, and immunological lab values among patients diagnosed with systemic lupus erythematosus pre- and post-anifrolumab treatment initiation: A large real-world analysis | Demetrios Psihopaidas | 13:15–13:30 |
| Oral presentations: Monday, November 9 | |||
| Abstract | Title | Presenter | Time (EST) |
| 1823 | Obinutuzumab induces histologic remission and deep kidney parenchymal B-cell depletion in patients with lupus nephritis: Exploratory analyses from a phase III trial | Richard Furie | 10:45–11:00 |
| 1844 | Adverse pregnancy outcomes in the lupus in prEGnAnCY (LEGACY) cohort: Anti-phosphatidylserine/prothrombin IgG antibodies are stronger predictors than lupus anticoagulant | Reem Farhat | 08:00–08:15 |
| 1862 | Post-treatment proteinuria imperfectly predicts histological remission in lupus nephritis: Repeat biopsy data from ReBioLup support reappraisal of trial endpoints | Ioannis Parodis | 13:00–13:15 |
| 1916 | Validation of Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) for evaluation of patients with cutaneous lupus erythematosus in clinical trials | Victoria Werth | 15:00–15:15 |
| Oral presentations: Tuesday, November 10 | |||
| Abstract | Title | Presenter | Time (EST) |
| 2839 | A new endpoint for SLE clinical trials: The Treatment Response Measure for Systemic Lupus Erythematosus Clinical Trials (TRM-SLE) | Eric Morand | 08:00–08:15 |
| 2870 | Toward improved patient-centered outcome assessment in SLE trials: Development of a novel patient reported outcomes set by the Lupus Accelerating Breakthroughs Consortium PRO measures working group | Madison Lewis | 13:15–13:30 |
| Oral presentations: Wednesday, November 11 | |||
| Abstract | Title | Presenter | Time (EST) |
| LB23 | A phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of afimetoran, an oral, once-daily equipotent TLR 7/8 inhibitor, in participants with active systemic lupus erythematosus | Kenneth Kalunian | 09:00–09:15 |
| Posters | |||
| Abstract | Title | Presenter | Date and time (EST) |
| 0259 | Cenerimod, a selective S1PR1 modulator, induces changes in BCR and TCR repertoire in systemic lupus erythematosus: Post-hoc analysis from the placebo-controlled phase 2b CARE trial | Mark Murphy | Sunday, November 8, 10:30–12:30 |
| 0269 | Efficacy and safety of edecesertib (GS-5718) for the treatment of cutaneous lupus erythematosus: Results from a Ph2a study | Victoria Werth | Sunday, November 8, 10:30–12:30 |
| 0280 | Safety and efficacy of AZD0120 (GC012F), a dual-targeting CD19/BCMA CAR-T cell therapy, in refractory systemic lupus erythematosus: Phase 1/2 interim results | Qiong Fu | Sunday, November 8, 10:30–12:30 |
| 1220 | Exploratory urinary biomarkers from an open-label phase 1/2 study of rapcabtagene autoleucel (YTB323) suggest reduced intrarenal inflammation in severe refractory systemic lupus erythematosus | Andrea Fava | Monday, November 9, 10:30–12:30 |
| 1231 | Low five year mortality in SLE treated with belimumab: Findings from the prospective, global, SABLE registry | Ronald van Vollenhoven | Monday, November 9, 10:30–12:30 |
| 1234 | Off-the-shelf CD19 CAR T-cell therapy demonstrates feasibility of outpatient administration, expanding access to community-based care | Aikaterini Thanou | Monday, November 9, 10:30–12:30 |
| 1240 | Safety and efficacy of subcutaneous ianalumab (VAY736) post-b cell recovery in patients with systemic lupus erythematosus: End-of-study results from a phase 2, multicenter, randomized, double-blind, placebo-controlled study | Edward Vital | Monday, November 9, 10:30–12:30 |
| 1296 | Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): Application to a phase 3 trial of dapirolizumab pegol | Eric Morand | Monday, November 9, 10:30–12:30 |
| 2213 | Long-term multidomain clinical response to deucravacitinib in SLE: Four-year integrated analyses from a phase 2 randomized study and its long-term extension | Ronald van Vollenhoven | Tuesday, November 10, 10:30–12:30 |
| 2216 | Obecabtagene autoleucel (obe-cel), a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, in adults and adolescents with severe, refractory systemic lupus erythematosus (srSLE): Findings from the phase I CARLYSLE study | Claire Roddie | Tuesday, November 10, 10:30–12:30 |
| 2224 | Safety and efficacy of enpatoran in lupus: Results up to 109 weeks of the phase II WILLOW long-term extension study | Eric Morand | Tuesday, November 10, 10:30–12:30 |
| LB04 | Durable responses at ≥ 12 months with zola-cel in severe refractory systemic lupus erythematosus: Safety, efficacy, and translational findings from the full phase 1 Breakfree-1 cohort | Emily Littlejohn | Tuesday, November 10, 10:30–12:30 |
| LB17 | Mesenchymal stromal cells for refractory lupus: Results from the phase II multicenter double-blind, placebo-controlled trial | Gary Gilkeson | Tuesday, November 10, 10:30–12:30 |
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
